Beaumont

## Beaumont Laboratory

Laboratory Bulletin

# Selective Suppression of Quinolone Susceptibility for Enterobacteriaceae

**Effective Date: July 26,2018**

Antibiotic misuse and overuse is associated with multiple adverse effects, including drug reactions, development of antibiotic resistance, and *Clostridium difficile* infection. Fluoroquinolones (e.g. ciprofloxacin, levofloxacin, moxifloxacin) are a class of antibacterials frequently associated with all of these issues, and in recent years these adverse effects have led to numerous FDA safety warnings (for the most recent alert, see https://www.fda.gov/Drugs/DrugSafety/ucm500143.htm).
Specifically, the FDA is now advising against the use of fluoroquinolones for treatment of acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections in patients who have other treatment options.

The laboratory will no longer report susceptibility test results for fluoroquinolones for Enterobacteriaceae (e.g. *Escherichia coli*, *Klebsiella*, *Enterobacter*, etc) from sites other than blood when isolates are susceptible to all other agents. Fluoroquinolone results will still be reported for bloodstream isolates and for *Salmonella* species.

If you have questions, please contact Client Services (1-800-551-0488, option 5).

---

**Date submitted:** July 26, 2018
**Submitted by:** Paul Chittick, MD, Director of Antimicrobial Stewardship
Bobby Boyanton, M.D., Medical Director, Microbiology and Molecular Pathology
Barbara Robinson-Dunn, PhD, D(ABMM), F(AAM), Technical Director, Microbiology


*Beaumont Laboratory*
*Customer Service*
**1-800-551-0488**

**28050 Grand River Ave.**
**Farmington Hills, MI 48336**

**468 Cadieux Road**
**Grosse Pointe, MI 48230**

**3601 West 13 Mile Road**
**Royal Oak, MI 48073**

**44201 Dequindre Road**
**Troy, MI 48085**

www.beaumontlaboratory.com